Livagen (Khavinson)
Livagen (Lys-Glu-Asp-Ala) is a Khavinson bioregulator tetrapeptide targeting hepatic (liver) tissue gene expression. It supports hepatocyte function, liver detoxification pathways, and hepatic regeneration. Developed for age-related liver function decline and hepatoprotection.
Starting dose. 200 mcg — Daily
SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Livagen modulates gene expression in hepatocytes, upregulating genes involved in Phase I/II detoxification enzymes, albumin synthesis, bile acid metabolism, and hepatic regeneration. Supports liver tissue maintenance at the gene expression level.
Days 1-10: Gene changes initiated.
Weeks 2-8: Hepatic gene programs established.
Months: Sustained liver support.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Evidence boundary from the checked abstract: Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 200 mcg daily; SubQ injection; 10 day course. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
Hepatoprotection
Bioregulatory gene expression modulation targeting liver-specific pathways. Russian clinical support.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
Gene expression changes persist beyond peptide clearance
Enzymatic degradation (peptidases)
Storage. Standard BAC water 2-8C. 21-28 days.
Not FDA-approved. Research peptide.
Put it to work
Open Livagen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Livagen in the app →Go deeper
The complete Livagen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.